A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation (2012)
- Authors:
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP
- Unidade: FMRP
- DOI: 10.2174/138161212802884681
- Subjects: CANNABIS; ANTIPSICÓTICOS; TRANSTORNOS PSICÓTICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Current Phamaceutical Design
- ISSN: 1873-4286
- Volume/Número/Paginação/Ano: v. 18, n. 32, p. 5131-5140, 2012
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
ZUARDI, Antonio Waldo et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Phamaceutical Design, v. 18, n. 32, p. 5131-5140, 2012Tradução . . Disponível em: https://doi.org/10.2174/138161212802884681. Acesso em: 31 mar. 2026. -
APA
Zuardi, A. W., Crippa, J. A. de S., Hallak, J. E. C., Bhattacharyya, S., Atakan, Z., Martín-Santos, R., et al. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Phamaceutical Design, 18( 32), 5131-5140. doi:10.2174/138161212802884681 -
NLM
Zuardi AW, Crippa JA de S, Hallak JEC, Bhattacharyya S, Atakan Z, Martín-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Internet]. Current Phamaceutical Design. 2012 ; 18( 32): 5131-5140.[citado 2026 mar. 31 ] Available from: https://doi.org/10.2174/138161212802884681 -
Vancouver
Zuardi AW, Crippa JA de S, Hallak JEC, Bhattacharyya S, Atakan Z, Martín-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Internet]. Current Phamaceutical Design. 2012 ; 18( 32): 5131-5140.[citado 2026 mar. 31 ] Available from: https://doi.org/10.2174/138161212802884681 - Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
- Effects of minocycline on regional cerebral blood flow in schizophrenia
- Canabidiol: possíveis aplicacões terapêuticas em psicopatologias
- Cannabidiol, a cannabis sativa constituent, as an antipsycholic drug
- Possible therapeutic uses of cannabidiol in anxiety disorders and schizophrenia
- Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]
- Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder
- Cannabidiol and neuroprotection: evidence from preclinical studies
- Cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line MO3.13
- Marijuana, feijoada and the debate on drug legalization
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
